TY - CHAP M1 - Book, Section TI - Cutaneous Drug Eruptions A1 - Curry, Jonathan L. A1 - Chu, Emily Y. A1 - Tetzlaff, Michael T. A2 - Barnhill, Raymond L. A2 - Crowson, A. Neil A2 - Magro, Cynthia M. A2 - Piepkorn, Michael W. A2 - Kutzner, Heinz A2 - Desman, Garrett T. Y1 - 2020 N1 - T2 - Barnhill's Dermatopathology, 4e AB - Advances in molecular techniques and the ability to perform deep cancer phenotyping has ushered in the era of precision cancer medicine.1 The field of medical oncology has witnessed a paradigm shift in the treatment of cancer with targeted cancer therapy with small molecule inhibitors (Nibs) and monoclonal antibodies (Mabs). Given the frequency of adverse cutaneous reactions encountered from Nibs and Mabs, the field of dermatopathology has now entered an era of “oncologic dermatopathology.” As a result, increasingly dermatopathologists are confronted with a diverse array of adverse cutaneous reactions developing in patients undergoing novel anticancer treatments. Knowledge of the clinical features of these adverse reactions will aid dermatopathologists in making accurate diagnoses. SN - PB - McGraw Hill Education CY - New York, NY Y2 - 2024/11/03 UR - dermatology.mhmedical.com/content.aspx?aid=1178398187 ER -